

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION FRAMEWORK AGREEMENT BY CR BOYA BIO-PHARMACEUTICAL

This is a voluntary announcement made by China Resources Pharmaceutical Group Limited (the "**Company**"), together with its subsidiaries, the "**Group**").

STRATEGIC COOPERATION FRAMEWORK AGREEMENT

China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司) ("**CR Boya Bio-pharmaceutical**"), a non-wholly owned subsidiary of the Company, has recently signed a strategic cooperation framework agreement ("**Strategic Cooperation Framework Agreement**") with Shenzhen Gaotejia Investment Group Company Limited (深圳市高特佳投資集團有限公司) ("**Gaotejia Group**") and Guangdong Danxia Bio-Pharmaceutical Company Limited (廣東丹霞生物製藥有限公司) ("**Danxia-Bio**"). Pursuant to the Strategic Cooperation Framework Agreement, the parties have primarily made the following strategic cooperation agreements:

- (i) **Cooperation in operation and management:** CR Boya Bio-pharmaceutical will make use of its own advantages to provide comprehensive services to Danxia-Bio, enhance Danxia-Bio's risk adaptability and jointly strengthen and optimize Danxia-Bio's businesses through regulating its operation and management and strengthening business cooperation and innovation.
- (ii) **Joint exploration of equity cooperation:** CR Boya Bio-pharmaceutical, as a limited partner of Shenzhen Gaotejia Qianhai Prestige Investment Partnership (Limited Partnership) (深圳市高特佳前海優享投資合伙企業(有限合伙)) ("**Qianhai Prestige Fund**"), which is the controlling shareholder of Danxia-Bio, holds approximately 1.31% interest in Qianhai Prestige Fund as at the date of this announcement, and therefore CR Boya Bio-pharmaceutical indirectly holds a minority interest in Danxia-Bio. Gaotejia Group has agreed that in the process of improving and optimising the shareholding structure of Danxia-Bio, it will concurrently facilitate the adjustment of the limited partnership interest in Danxia-Bio indirectly held by CR Boya Bio-pharmaceutical through Qianhai Prestige Fund to become direct shareholder of Danxia-Bio. In the event of any change in the structure of Qianhai Prestige Fund or Danxia-Bio (including any transfer of shareholding or increase in shareholding), Gaotejia Group will procure CR Boya Bio-pharmaceutical to enjoy a priority right of cooperation. The above-mentioned equity cooperation will be subject to the assessment and approval process of the parties in accordance with the regulations of the State-owned Assets Supervision and Administration Commission, the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

The Strategic Cooperation Framework Agreement is a framework agreement and does not involve a specific amount of consideration. Specific matters involved thereunder are subject to the signing of separate formal agreements and the contents of such formal agreements signed by the parties shall prevail, and are subject to the relevant approval process and disclosure obligation. Accordingly, the Strategic Cooperation Framework Agreement does not currently constitute a notifiable transaction under Chapter 14 or a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION

The strategic cooperation under the Strategic Cooperation Framework Agreement aims to strengthen the in-depth cooperation between the parties in the pharmaceutical and healthcare industry, establish a strategic cooperation relationship in line with the common interests of the parties, capitalize on their respective strengths, realize their complementary advantages, and achieve a win-win situation for each other, thereby enabling CR Boya Bio-pharmaceutical and the Group to enhance their overall competitiveness.

INFORMATION OF THE PARTIES

CR Boya Bio-pharmaceutical is a company incorporated in the People's Republic of China. The shares of CR Boya Bio-pharmaceutical are listed on the Shenzhen Stock Exchange. As at the date of this announcement, the Company indirectly holds approximately 29.28% of the total share capital and approximately 40.59% voting rights in the total share capital of CR Boya Bio-pharmaceutical, and therefore, CR Boya Bio-pharmaceutical is a subsidiary of the Company.

As at the date of this announcement, Gaotejia Group directly holds approximately 11.31% of the total share capital of CR Boya Bio-pharmaceutical, and is therefore a substantial shareholder of CR Boya Bio-pharmaceutical. Gaotejia Group is the managing partner of Qianhai Prestige Fund, and indirectly controls Danxia-Bio through its shareholding in Qianhai Prestige Fund.

This announcement is made by the Company on a voluntary basis to provide information to its shareholders and potential investors. Shareholders and potential investors of the Company are reminded to exercise caution in dealing with the securities of the Company.

For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese versions shall prevail.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 20 April 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.